Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday

Viridian Therapeutics (NASDAQ:VRDN) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Viridian Therapeutics to post earnings of ($0.88) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Viridian Therapeutics Trading Up 4.7%

NASDAQ VRDN opened at $29.40 on Wednesday. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $34.29. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average of $31.19 and a 200-day moving average of $26.28. The company has a market cap of $2.81 billion, a PE ratio of -9.74 and a beta of 0.98.

Wall Street Analysts Forecast Growth

A number of analysts have commented on VRDN shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $40.00 price target on shares of Viridian Therapeutics in a research note on Thursday, November 6th. Evercore reaffirmed an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Wells Fargo & Company lifted their price target on Viridian Therapeutics from $26.00 to $29.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Needham & Company LLC reissued a “buy” rating and set a $42.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, February 4th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $61.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, November 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $42.64.

Insiders Place Their Bets

In related news, insider Jennifer Tousignant sold 2,272 shares of the business’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total value of $70,795.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.65% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in shares of Viridian Therapeutics in the third quarter valued at about $52,000. US Bancorp DE boosted its holdings in Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares during the period. Persistent Asset Partners Ltd acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $176,000. Ensign Peak Advisors Inc acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $201,000. Finally, WINTON GROUP Ltd bought a new position in shares of Viridian Therapeutics during the fourth quarter worth approximately $221,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.